TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Duloxetine 60/120mg Versus Placebo in the Treatment of Fibromyalgia Syndrome
Brief Summary: To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome.


Options:
A: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo | Arm Label: Pregabalin+Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Pregabalin, Drug: Placebo | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin, Drug: Placebo | Arm Label: Duloxetine + Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Pregabalin, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine, Duloxetine + Pregabalin, Pregabalin+Duloxetine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Duloxetine + Pregabalin, Pregabalin, Pregabalin+Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine, Duloxetine + Pregabalin, Pregabalin, Pregabalin+Duloxetine
D: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Duloxetine 60/120mg Versus Placebo in the Treatment of Fibromyalgia Syndrome
Brief Summary: To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome.


Options:
A: Arm Label: All patients; Type: N/A; Interventions: N/A
B: Arm Label: Vitamin D3 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: Vitamin D3 600 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 4000 IU | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 600 IU
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: Arm I (omega-3 fatty acid); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 Fatty Acid | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acid; Assigned to Arm(s): Arm I (omega-3 fatty acid) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (placebo)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the effectiveness of a Head Start-based early intervention for designed to improve asthma management skill and practices of parents, pre-school children and Head Start staff.


Options:
A: Arm Label: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Arm Label: fluticasone propionate 2 x 100 mcg; Type: OTHER; Interventions: Drug: fluticasone propionate 2 x 100 mcg | Intervention Type: DRUG; Name: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Assigned to Arm(s): Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Intervention Type: DRUG; Name: fluticasone propionate 2 x 100 mcg; Assigned to Arm(s): fluticasone propionate 2 x 100 mcg
B: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A
D: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the effectiveness of a Head Start-based early intervention for designed to improve asthma management skill and practices of parents, pre-school children and Head Start staff.


Options:
A: Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: attention control; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Set of supportive tools/measures vs. standard care; Assigned to Arm(s): N/A
C: Arm Label: Arm 1: Collaborative Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Interventions | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Collaborative Care Interventions; Assigned to Arm(s): Arm 1: Collaborative Care Intervention
D: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the effectiveness of a Head Start-based early intervention for designed to improve asthma management skill and practices of parents, pre-school children and Head Start staff.


Options:
A: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A
B: Arm Label: Control Subjects; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Subjects; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Subjects | Intervention Type: BEHAVIORAL; Name: Intervention Subjects; Assigned to Arm(s): Intervention Subjects
C: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the effectiveness of a Head Start-based early intervention for designed to improve asthma management skill and practices of parents, pre-school children and Head Start staff.


Options:
A: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA
B: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
D: Arm Label: Interventional group: Period 2; Type: EXPERIMENTAL; Interventions: Drug: salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training | Arm Label: Control group: Period 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: salmeterol/fluticasone propionate 50/250 µg | Arm Label: Subjects receiving salmeterol/fluticasone propionate: Period 1; Type: EXPERIMENTAL; Interventions: Drug: salmeterol/fluticasone propionate 50/250 µg | Intervention Type: DRUG; Name: salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training; Assigned to Arm(s): Interventional group: Period 2 | Intervention Type: DRUG; Name: salmeterol/fluticasone propionate 50/250 µg; Assigned to Arm(s): Control group: Period 2, Subjects receiving salmeterol/fluticasone propionate: Period 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CHD Lifestyle Modification for Latinas With Diabetes
Brief Summary: The Viva Bien! trial will comprehensively evaluate a multiple risk factor intervention (diet, physical activity, stress management, social support, and smoking cessation) in a randomized effectiveness trial, which will be offered in English and Spanish to diabetic Latinas.


Options:
A: Arm Label: CBT+ Contact; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT+ Contact | Arm Label: CBT+ Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: CBT+ Exercise | Intervention Type: BEHAVIORAL; Name: CBT+ Contact; Assigned to Arm(s): CBT+ Contact | Intervention Type: BEHAVIORAL; Name: CBT+ Exercise; Assigned to Arm(s): CBT+ Exercise
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mediterranean Diet, Behavioral: Physical Activity, Behavioral: Stress Management, Behavioral: Social Support, Behavioral: Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Mediterranean Diet; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Stress Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Social Support; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Smoking Cessation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
C: Arm Label: PA+ Smoking Cessation (LMPA); Type: EXPERIMENTAL; Interventions: Behavioral: PA+ Smoking Cessation (LMPA) | Arm Label: Standard Care Smoking Counseling (SCC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care Smoking Counseling (SCC) | Intervention Type: BEHAVIORAL; Name: PA+ Smoking Cessation (LMPA); Assigned to Arm(s): PA+ Smoking Cessation (LMPA) | Intervention Type: BEHAVIORAL; Name: Standard Care Smoking Counseling (SCC); Assigned to Arm(s): Standard Care Smoking Counseling (SCC)
D: Arm Label: Standard Care plus Wellness Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Treatment, Drug: Nicotine Patch, Behavioral: Wellness Program | Arm Label: Standard Care plus Exercise Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Treatment, Drug: Nicotine Patch, Behavioral: Aerobic Exercise | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Treatment; Assigned to Arm(s): Standard Care plus Exercise Program, Standard Care plus Wellness Program | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Standard Care plus Exercise Program, Standard Care plus Wellness Program | Intervention Type: BEHAVIORAL; Name: Wellness Program; Assigned to Arm(s): Standard Care plus Wellness Program | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): Standard Care plus Exercise Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Brief Summary: This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.


Options:
A: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Poractant alfa (Curosurf®) | Intervention Type: DRUG; Name: Poractant alfa (Curosurf®); Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Very early surfactant and bubble NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: bubble NCPAP | Intervention Type: OTHER; Name: Very early surfactant and bubble NCPAP; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: bubble NCPAP; Assigned to Arm(s): 2
D: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Brief Summary: This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.


Options:
A: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen
B: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Poractant alfa (Curosurf®) | Intervention Type: DRUG; Name: Poractant alfa (Curosurf®); Assigned to Arm(s): 2
D: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Brief Summary: This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Very early surfactant and bubble NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: bubble NCPAP | Intervention Type: OTHER; Name: Very early surfactant and bubble NCPAP; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: bubble NCPAP; Assigned to Arm(s): 2
B: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Poractant alfa (Curosurf®) | Intervention Type: DRUG; Name: Poractant alfa (Curosurf®); Assigned to Arm(s): 2
D: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Brief Summary: This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.


Options:
A: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen
B: Arm Label: cerebral oximetry + treatment guideline; Type: EXPERIMENTAL; Interventions: Device: cerebral oximeter | Intervention Type: DEVICE; Name: cerebral oximeter; Assigned to Arm(s): cerebral oximetry + treatment guideline
C: Arm Label: Near Infrared Spectroscopy; Type: EXPERIMENTAL; Interventions: Device: Near Infrared Spectroscopy | Arm Label: Pulse-oximetry; Type: OTHER; Interventions: Device: Pulse-oximetry | Intervention Type: DEVICE; Name: Near Infrared Spectroscopy; Assigned to Arm(s): Near Infrared Spectroscopy | Intervention Type: DEVICE; Name: Pulse-oximetry; Assigned to Arm(s): Pulse-oximetry
D: Arm Label: Cerebral NIRS oximetry + treatment guideline based on reading; Type: EXPERIMENTAL; Interventions: Device: Cerebral NIRS oximetry | Arm Label: Blinded cerebral NIRS oximetry; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cerebral NIRS oximetry; Assigned to Arm(s): Cerebral NIRS oximetry + treatment guideline based on reading

Answer: A